English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Aging is associated with loss of diversity in gut microbiota leading to dysbiosis; a condition linked with cognitive/physical frailty. Age-related health benefits have been ascribed to the renin-angiotensin system (RAS), mediated via the angiotensin-converting-enzyme-2 (ACE2)/angiotensin (1-7) or Ang(1-7) axis. A genetically modified probiotic secreting Ang(1-7) or GMP-A, targeting the gut, has been described for diabetes and hypertension; however, we are the first to provide proof of concept for its use in aging. We report that GMP-A increases circulating levels of Ang(1-7) when orally-administered over 4 weeks in aged F344/BN rats. Ongoing experiments examine GMP-A impact on distal tissues (muscle/brain). GMP-A provides translational advantages including ease of administration, production cost, and burden for regulatory approval.

THERAPEUTIC DELIVERY OF ANG(1-7) VIA GENETICALLY MODIFIED PROBIOTIC: A DOSING STUDY